Neil E Kay Selected Research

Multiple Myeloma

1/2022	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.
10/2015	Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs.
11/2009	Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.
5/2006	Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
5/2002	Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
2/2002	Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Neil E Kay Research Topics

Disease

94	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 10/2002
28	Neoplasms (Cancer) 01/2022 - 01/2004
20	Disease Progression 10/2022 - 01/2002
8	Lymphoma (Lymphomas) 01/2022 - 08/2004
8	Leukemia 06/2015 - 12/2003
7	Lymphocytosis 01/2022 - 01/2013
6	Multiple Myeloma 01/2022 - 02/2002
6	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 04/2007
5	Residual Neoplasm 01/2022 - 01/2007
5	Chromosome Aberrations (Chromosome Abnormalities) 07/2014 - 09/2006
4	Infections 07/2014 - 01/2004
3	Atrial Fibrillation 01/2021 - 01/2017
3	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 04/2006
3	Fatigue 12/2018 - 10/2013
2	Agammaglobulinemia (Hypogammaglobulinemia) 01/2022 - 09/2015
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 10/2011
2	Cytokine Release Syndrome 01/2021 - 01/2019
2	Tumor Lysis Syndrome 10/2020 - 12/2018
2	Diarrhea 12/2018 - 07/2014
2	Cytopenia 11/2018 - 04/2010
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2018 - 02/2006
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2015 - 07/2010
2	Lymphoid Leukemia 07/2014 - 12/2003
2	Autoimmune Diseases (Autoimmune Disease) 01/2011 - 06/2009
2	Hypoxia (Hypoxemia) 03/2010 - 04/2008
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2006 - 12/2003
1	Human Influenza (Influenza) 12/2021
1	Hodgkin Disease (Hodgkin's Disease) 01/2021
1	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 01/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2020
1	Trisomy (Trisomies) 01/2020
1	Neuroinflammatory Diseases 01/2019
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019
1	Hypertension (High Blood Pressure) 12/2018
1	Hemorrhage 12/2018
1	Weight Loss (Weight Reduction) 12/2018
1	Chronic Disease (Chronic Diseases) 12/2018
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 10/2018
1	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 10/2018
1	Purpura 10/2018

Drug/Important Bio-Agent (IBA)

18	ibrutinibIBA 10/2022 - 07/2014
16	Rituximab (Mabthera)FDA Link 01/2019 - 01/2007
9	Biological ProductsIBA 01/2022 - 01/2002
9	Pentostatin (Nipent)FDA LinkGeneric 01/2019 - 01/2004
9	Proteins (Proteins, Gene)FDA Link 06/2015 - 05/2002
8	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2020 - 08/2004
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 01/2007
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2007
7	Immunoglobulins (Immunoglobulin)IBA 01/2015 - 05/2002
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2016 - 08/2004
5	Pharmaceutical PreparationsIBA 09/2015 - 07/2007
4	venetoclaxIBA 10/2022 - 01/2020
4	Chimeric Antigen ReceptorsIBA 01/2022 - 01/2019
4	Alemtuzumab (Campath)FDA Link 01/2019 - 10/2008
4	ofatumumab FDA Link 12/2018 - 03/2011
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2022 - 03/2013
3	AntigensIBA 01/2022 - 01/2008
3	B-Cell Maturation AntigenIBA 01/2022 - 01/2021
3	VaccinesIBA 01/2022 - 07/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 05/2006
3	Prednisone (Sone)FDA LinkGeneric 09/2015 - 01/2004
3	MicroRNAs (MicroRNA)IBA 06/2015 - 01/2011
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2015
2	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2022 - 01/2021
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021 - 07/2010
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 07/2010
2	fludarabineIBA 01/2019 - 01/2009
2	serum P-component (CIt)IBA 01/2019 - 11/2013
2	Bendamustine Hydrochloride FDA Link 08/2017 - 01/2015
2	Monoclonal AntibodiesIBA 11/2016 - 02/2004
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2015 - 02/2011
2	idelalisibIBA 05/2015 - 01/2013
2	polyphenon EIBA 01/2013 - 08/2009
2	TeaIBA 01/2013 - 08/2004
2	IntegrinsIBA 01/2013 - 10/2011
2	Protein Kinases (Protein Kinase)IBA 01/2011 - 09/2006
2	purineIBA 04/2010 - 04/2006
2	Complement System Proteins (Complement)IBA 06/2009 - 12/2008
2	Chlorambucil (Leukeran)FDA Link 01/2009 - 01/2004
2	NF-kappa B (NF-kB)IBA 11/2008 - 07/2007
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2008 - 08/2004
2	B-Cell Activating FactorIBA 02/2006 - 10/2002
1	Herpes Zoster VaccineIBA 01/2022
1	Influenza Vaccines (Influenza Vaccine)FDA Link 12/2021
1	CateninsIBA 01/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021
1	3- (5- amino- 2- methyl- 4- oxoquinazolin- 3(4H)- yl)piperidine- 2,6- dioneIBA 01/2021
1	Exportin 1 ProteinIBA 01/2021
1	ChemokinesIBA 01/2021
1	Biological FactorsIBA 12/2020
1	thiamine triphosphorate (TTP)IBA 01/2019
1	Long Noncoding RNAIBA 01/2019
1	IGF-I-IGFBP-3 complex FDA Link 01/2019
1	Axl Receptor Tyrosine KinaseIBA 12/2018
1	Inosine Triphosphate (ITP)IBA 10/2018

Therapy/Procedure

40	Therapeutics 01/2022 - 01/2004
3	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2021
3	Drug Therapy (Chemotherapy) 02/2009 - 04/2006
2	Aftercare (After-Treatment) 01/2019 - 01/2009
1	Duration of Therapy 10/2018